Increasing prevalence of obesity and clustered cardiometabolic risk: Can treatment of the underlying cause reverse the trends?

Critical Pathways in Cardiology

Volumn 6, Issue 2, 2007, Pages 41-45

  Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Mail Stop A601 ^*  (United States)

Author keywords

Abdominal adiposity; Cardiovascular disease; Diabetes; Dyslipidemias; Hypertension; Metabolic syndrome; Obesity; Visceral adiposity

Indexed keywords

AMFEPRAMONE; BENZPHETAMINE; PHENDIMETRAZINE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNITED STATES; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; ICELAND; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES; WEIGHT LOSS;

EID: 34249936368     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318053d190     Document Type: Review

References (36)

1. Kim JK, Alley D, Seeman T, et al. Recent changes in cardiovascular risk factors among women and men. J Womens Health (Larchmt). 2006;15:734-746.
2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
3. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449.
5. Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden: US, 2005-2050. Diabetes Care. 2006;29:2114-2116.
6. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-211.
7. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
8. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
9. Blanck HM, Dietz WH, Galuska DA, et al. State-specific prevalence of obesity among adults-United States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:985-988.
10. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. Washington, DC: U.S. Department of Health and Human Services; 2000.
11. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004;109:837-842.
12. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
13. American Diabetes Association. Total prevalence of diabetes & pre-diabetes. [-American Diabetes Association website]. Available at: http://www.diabetes.org/diabetes-statistics/prevalence.jsp. Accessed February 2007.
14. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263-1268.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
16. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
17. Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47:699-713.
18. Jacobson TA, Case CC, Roberts S, et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004;6:353-362.
19. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
21. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
22. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295-309.
23. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.
24. Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113:2943-2946.
25. National Institutes of Health/National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000:80.
26. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
27. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66:1625-1656.
28. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(suppl 3):S12-S23.
29. Leung WY, Neil Thomas G, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther. 2003;25:58-80.
30. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-1446.
31. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
32. Sjöström L, Rissanen A, Andersen T, et al., for the European Multicentre Orlistat Study Group. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-172.
33. Xenical -[package insert]. Nutley, NJ: Roche Laboratories, revised January 2005.
34. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198.
35. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160:2185-2191.
36. Meridia -[package insert]. North Chicago, IL: Abbott Laboratories, revised August, 2006.